New unit to bring Novo Nordisk closer to goal of using RNA and gene therapies across all treatment areas
Novo Nordisk has begun the work of establishing a new internal unit as part of a "significant investment" in RNA and gene therapies. The long-term aim is to use these therapies across all treatment areas.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk, Denmark's biggest pharmaceutical company, has established a new unit with the ambition of making RNA and gene therapy available across all of its therapy areas, Senior Vice President of Global Research Technologies at Novo Nordisk tells Medwatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk bets on RNA in several business areas
For subscribers
Novo Nordisk creates new RNA and gene therapy unit
For subscribers
.jpg&w=384&q=75)
